Production of protein solid materials
The use of a cell-free protein synthesis system enables rapid and efficient production of protein crystals by expressing crystalline proteins, addressing the time and effort challenges of existing methods.
Patent Information
- Application Number
- JP2021537385
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-08-07
- Filing Date
- 2020-08-06
- Publication Date
- 2024-11-07
- Estimated Expiration
- 2040-08-06
AI Technical Summary
Existing methods for producing protein crystals, such as those described in Patent Document 1 and Non-Patent Document 1, require significant time and effort.
A method involving a cell-free protein synthesis system where a nucleic acid encoding a crystalline protein is added, expressed, and allowed to form crystals over a predetermined period, utilizing proteins like cytoplasmic polyhedral, nuclear polyhedral, insecticidal, cathepsin B, reovirus nonstructural, or fusion proteins to achieve rapid crystallization.
Protein crystals can be obtained in a significantly shorter time, typically within one day, with reduced effort and labor, while maintaining structural integrity for analysis.
Smart Images

Figure 0007578960000001 
Figure 0007578960000002 
Figure 0007578960000003
Abstract
Description
[Technical field]
[0001] The present invention relates to the production of a protein solid material. This application claims priority based on Japanese Patent Application No. 2019-145456, filed on August 7, 2019, the contents of which are incorporated herein by reference. [Background technology]
[0002] Pathogens that cause polyhedrosis in insects such as silkworms include the nuclear polyhedrosis virus (Nucleopolyhedrovirus, NPV), which causes nuclear polyhedrosis, and the cytoplasmic polyhedrosis virus (Cypovirus, CPV), which causes cytoplasmic polyhedrosis. The former is a DNA virus, whereas the latter is an RNA virus. NPV is widely used by many researchers as a baculovirus vector.
[0003] In the later stages of infection, the polyhedrosis virus produces large amounts of inclusion bodies called polyhedra within the infected cells, amounting to approximately half of the total cellular protein, and encapsulates many virus particles within them. The virus encapsulated in the polyhedra is protected from inactivating effects from the outside world, such as ultraviolet light and heat, and can maintain infectivity for a long period of time.
[0004] Polyhedra are stable and do not dissolve in many solvents or detergents, but dissolve under alkaline conditions with a pH of about 10 or higher. When virus particles enclosed in polyhedra are ingested by insects, the polyhedra are dissolved by the high pH of the gut, releasing the virus particles and causing infection.
[0005] The above-mentioned polyhedra are formed by spontaneously crystallizing polyhedrin, a polyhedrin protein, within cells. In addition to polyhedrin, other proteins known to spontaneously crystallize within cells include, for example, insecticidal proteins of Bacillus thuringiensis. In this specification, a protein that spontaneously forms crystals is referred to as a crystalline protein, and the crystals thus formed are referred to as protein crystals.
[0006] Meanwhile, in recent years, research has been conducted on the utilization of polyhedra. For example, Patent Document 1 describes a method for producing a polyhedron-target molecule complex in which a target molecule is encapsulated in a polyhedron. In addition, Non-Patent Document 1 describes that a gene encoding a fusion protein with H1α-helix present at the N-terminus of a polyhedrin protein, which is a polyhedron protein, is coexpressed in a cell together with a gene encoding the polyhedrin protein, thereby preparing a polyhedron in which a fusion protein is encapsulated in the polyhedron crystal of a cytoplasmic polyhedrosis virus. [Prior art documents] [Patent documents]
[0007] [Patent Document 1] JP 2018-033404 A [Non-patent literature]
[0008] [Non-Patent Document 1] Ijiri H., et al., Structure-based targeting of bioactive proteins into cypovirus polyhedra and application to immobilized cytokines for mammalian cell culture., Biomaterials, 30 (26), 4297-4308, 2009 Summary of the Invention [Problem to be solved by the invention]
[0009] However, the methods described in Patent Document 1 and Non-Patent Document 1 require a great deal of time and effort to obtain polyhedral protein crystals. Therefore, the present invention provides a technique for obtaining protein crystals in a short time with little effort. [Means for solving the problem]
[0010] The present invention includes the following aspects. [1] A method for producing protein crystals, comprising: a step (a) of adding a nucleic acid encoding a crystalline protein to a protein synthesis system; and a step (b) of incubating the protein synthesis system for a predetermined period of time until the crystalline protein encoded by the added nucleic acid is expressed and the expressed crystalline protein completes the formation of crystals, wherein the protein synthesis system is a cell-free protein synthesis system. [2] The method for producing a protein crystal according to [1], wherein the crystalline protein is a protein according to any one of (A) to (C) below: (A) Cytoplasmic polyhedrin protein, nuclear polyhedrin protein, insecticidal protein, cathepsin B, insecticidal protein, reovirus nonstructural protein (μNS), Crystalline Inclusion Protein A (CipA), or Fusolin protein (B) A protein having an amino acid sequence in which one or more amino acids have been deleted, substituted or added in the amino acid sequence of the protein (A) and having crystal-forming ability. (C) A fusion protein of the protein (A) or (B) with a target peptide. [3] The method for producing a protein crystal according to [1], wherein the crystalline protein is one selected from the group consisting of the following (i), (ii), (iii) and (iv): (i) A protein consisting of the amino acid sequence set forth in SEQ ID NO: 1, or a protein consisting of the amino acid sequence set forth in SEQ ID NO: 1 in which one or more amino acids have been deleted, substituted or added, and having the ability to form polyhedra. (ii) A protein consisting of the amino acid sequence set forth in SEQ ID NO: 2, or a protein consisting of the amino acid sequence set forth in SEQ ID NO: 2 in which one or more amino acids have been deleted, substituted or added, and having the ability to form polyhedra. (iii) A protein consisting of the amino acid sequence set forth in SEQ ID NO: 18, or a protein consisting of the amino acid sequence set forth in SEQ ID NO: 18 in which one or more amino acids have been deleted, substituted or added, and having crystal-forming ability. (iv) A fusion protein having polyhedron-forming ability, in which the 70th to 77th amino acids in the amino acid sequence set forth in SEQ ID NO: 1 are replaced with a target peptide, or a protein having polyhedron-forming ability, which is an amino acid sequence in which one or more amino acids are deleted, substituted or added in the fusion protein. [4] The method for producing protein crystals according to [3], wherein the crystalline protein is (i) or (iv), and in the step (a), a nucleic acid encoding a fusion protein having a target peptide bound to the C-terminus of the amino acid sequence set forth in SEQ ID NO: 4, or the amino acid sequence set forth in SEQ ID NO: 4 in which one or more amino acids have been deleted, substituted or added, is further added to the protein synthesis system. [5] The method for producing a protein crystal according to any one of [1] to [4], wherein the cell-free protein synthesis system contains a target molecule having a molecular weight of 10 to 100,000. [6] A fusion protein having polyhedron-forming ability, in which the 70th to 77th amino acids of the amino acid sequence set forth in SEQ ID NO: 1 are replaced by a target peptide, or a fusion protein having polyhedron-forming ability, in which one or more amino acids are deleted, substituted or added in the amino acid sequence of the fusion protein. [7] Polyhedrons crystallized from the fusion protein described in [6]. [8] A polyhedron-target molecule complex in which a target molecule is encapsulated in the crystal structure of the crystallized polyhedron described in [7]. [9] A nucleic acid encoding the fusion protein described in [6].
[10] A kit for cell-free crystal production, comprising a nucleic acid encoding a crystalline protein and a reagent for a cell-free protein synthesis system.
[11] The kit for producing cell-free crystals according to
[10] , wherein the crystalline protein is any one of the proteins (A) to (C) below: (A) Cytoplasmic polyhedrin protein, nuclear polyhedrin protein, insecticidal protein, cathepsin B, insecticidal protein, luciferase, reovirus nonstructural protein (μNS), Crystalline Inclusion Protein A (CipA), or Fusolin protein (B) A protein having an amino acid sequence in which one or more amino acids have been deleted, substituted or added in the amino acid sequence of the protein (A) and having crystal-forming ability. (C) A fusion protein of the protein (A) or (B) with a target peptide.
[12] The kit for producing cell-free crystals described in
[10] , wherein the crystalline protein is one selected from the group consisting of (i), (ii), (iii) and (iv) below. (i) A protein consisting of the amino acid sequence set forth in SEQ ID NO: 1, or a protein consisting of the amino acid sequence set forth in SEQ ID NO: 1 in which one or more amino acids have been deleted, substituted or added, and having the ability to form polyhedra. (ii) A protein consisting of the amino acid sequence set forth in SEQ ID NO: 2, or a protein consisting of the amino acid sequence set forth in SEQ ID NO: 1 in which one or more amino acids have been deleted, substituted or added, and having polyhedron formation ability. (iii) A protein consisting of the amino acid sequence set forth in SEQ ID NO: 18, or a protein consisting of the amino acid sequence set forth in SEQ ID NO: 18 in which one or more amino acids have been deleted, substituted or added, and having crystal-forming ability. (iv) A fusion protein having polyhedron-forming ability, in which the 70th to 77th amino acids in the amino acid sequence set forth in SEQ ID NO: 1 are replaced with a target peptide, or a protein having polyhedron-forming ability, which is an amino acid sequence in which one or more amino acids are deleted, substituted or added in the fusion protein.
[13] The crystalline protein is (i) or (iv), The cell-free crystal production kit described in
[12] further comprises a nucleic acid encoding a fusion protein in which a target peptide is bound to the C-terminus of the amino acid sequence described in SEQ ID NO: 4, or the amino acid sequence described in SEQ ID NO: 4 in which one or more amino acids have been deleted, substituted or added. Effect of the Invention
[0011] According to the present invention, a technique for obtaining protein crystals in a short time with little effort can be provided. [Brief description of the drawings]
[0012] [Figure 1] This is an optical microscope image of polyhedral crystals obtained using a cell-free protein synthesis system. [Diagram 2] This is an SEM image of polyhedral crystals obtained by a cell-free protein synthesis system at 15°C. [Diagram 3] This is an SEM image of polyhedral crystals obtained by a cell-free protein synthesis system at 20°C. [Figure 4] This is the result of analyzing the three-dimensional structure of polyhedral crystals obtained using a cell-free protein synthesis system using X-ray structure analysis. [Figure 5A] 1 shows SEM images of crystals obtained from 220 μL and 55 μL solutions. [Figure 5B] This is an optical microscope image of crystals obtained from 22 μL of solution. [Figure 5C] This is an SEM image of crystals obtained from 22 μL of solution. [Figure 6A] This is a fluorescent image of GFP taken by irradiating excitation light onto a polyhedral crystal encapsulating GFP. [Figure 6B] This is the result of overlaying a bright-field image and a fluorescent image of a crystal. [Figure 7] This is a fluorescent image taken by irradiating excitation light onto a polyhedral crystal containing fluorescein. [Figure 8A] FIG. 2 is a schematic diagram of the three-dimensional structure of the polyhedrin protein in the vicinity of a substituted peptide. [Figure 8B]FIG. 2 is a schematic diagram of the three-dimensional structure of the polyhedrin protein in the vicinity of a substituted peptide. [Figure 8C] FIG. 2 is a schematic diagram of the three-dimensional structure of the polyhedrin protein in the vicinity of a substituted peptide. [Figure 8D] FIG. 2 is a schematic diagram of the three-dimensional structure of the polyhedrin protein in the vicinity of a substituted peptide. [Figure 9] These are optical microscope and SEM images of crystals formed from mutant polyhedrin protein. [Figure 10] 1 is a histogram of the size of crystals formed from mutant polyhedrin proteins. [Figure 11A] This is a photograph of the capillary used. [Figure 11B] This is a crystal of a mutant polyhedrin protein formed in a capillary. [Figure 12] These are the results of mass spectrometry of crystals formed from mutant polyhedrin protein. [Figure 13] Crystals formed from mutant polyhedrin protein were solubilized and analyzed by SDS-PAGE. [Figure 14A] This is an optical microscope image of Cry3A protein crystals prepared at 20°C. [Figure 14B] This is an optical microscope image of Cry3A protein crystals grown at 4°C. [Figure 14C] This is an SEM image of Cry3A protein crystals grown at 20°C. [Figure 14D] This is an SEM image of Cry3A protein crystals grown at 4°C. [Figure 15A] This is an optical microscope image of μNS protein crystals prepared at 20°C. [Figure 15B] This is an optical microscope image of μNS protein crystals prepared at 4°C. [Figure 15C] This is an SEM image of μNS protein crystals prepared at 20°C. [Figure 15D] This is an SEM image of μNS protein crystals prepared at 4°C. [Figure 16A]This is an optical microscope image of cathepsin B protein crystals prepared at 20°C. [Figure 16B] This is an optical microscope image of cathepsin B protein crystals prepared at 4°C. [Figure 16C] This is an SEM image of cathepsin B protein crystals prepared at 20°C. [Figure 16D] This is an SEM image of cathepsin B protein crystals prepared at 4°C. [Figure 17A] This is an optical microscope image of nuclear polyhedron protein crystals prepared at 20°C. [Figure 17B] This is an optical microscope image of nuclear polyhedron protein crystals prepared at 4°C. [Figure 17C] This is an SEM image of nuclear polyhedron protein crystals prepared at 20°C. [Figure 17D] This is an SEM image of nuclear polyhedron protein crystals prepared at 4°C. [Figure 18] This is an optical microscope image of CipA protein crystals prepared at 20°C. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0013] [Manufacturing method] In one embodiment, the present invention provides a method for producing protein crystals, comprising: a step (a) of adding a nucleic acid encoding a crystalline protein to a protein synthesis system; and a step (b) of incubating the protein synthesis system for a predetermined period of time until the crystalline protein encoded by the added nucleic acid is expressed and the expressed crystalline protein completes the formation of crystals, wherein the protein synthesis system is a cell-free protein synthesis system.
[0014] As used herein, a crystalline protein refers to a protein that can spontaneously self-assemble to form a crystal under physiological conditions, such as in the cytoplasm, and a protein crystal refers to a crystal formed from the above-mentioned crystalline protein.
[0015] The crystalline protein is not particularly limited as long as it is a protein that forms crystals in a cell-free protein synthesis system. Even if a non-crystalline protein does not naturally form crystals, if it becomes possible to form crystals in a cell-free protein synthesis system by techniques such as chemical modification of the protein, creation of a mutant, or fusion protein, the protein is also included in the crystalline protein in this specification.
[0016] More specific examples of crystalline proteins include proteins described in any one of (A) to (C) below. (A) Cytoplasmic polyhedrin protein, nuclear polyhedrin protein, insecticidal protein, cathepsin B, luciferase, reovirus nonstructural protein (μNS), Crystalline Inclusion Protein A (CipA), or Fusolin protein (B) A protein having an amino acid sequence in which one or more amino acids have been deleted, substituted or added in the amino acid sequence of the protein (A) and having crystal-forming ability. (C) A fusion protein of the protein (A) or (B) with a target peptide.
[0017] The cytoplasmic polyhedrin protein is a polyhedrin protein derived from a cytoplasmic polyhedrosis virus (Cypovirus, CPV), which is a pathogenic virus that causes cytoplasmic polyhedrosis. For example, the protein consisting of the amino acid sequence set forth in SEQ ID NO: 1 is a wild-type polyhedrin protein expressed by a cytoplasmic polyhedrosis virus that infects silkworm moths. Furthermore, the nuclear polyhedrin protein is a polyhedrin protein derived from a nuclear polyhedrosis virus (Nucleopolyhedrovirus, NPV), which is a pathogenic virus of nuclear polyhedrosis. For example, the protein consisting of the amino acid sequence set forth in SEQ ID NO: 2 is a wild-type polyhedrin protein expressed by a nuclear polyhedrosis virus that infects Autographa californica.
[0018] The insecticidal protein is an insecticidal protein produced by Bacillus thuringiensis. SEQ ID NO: 18 shows the amino acid sequence of the Cry3A protein produced by Bacillus thuringiensis.
[0019] Cathepsin B is a protease having endopeptidase and exopeptidase activities. Cathepsin B is a protein that forms crystals in cultured insect cells. SEQ ID NO: 19 shows the amino acid sequence of cathepsin B derived from Trypanosoma brucei.
[0020] Luciferase is a general term for enzymes that catalyze the chemical reactions that cause luminescent substances to emit light in bioluminescence, such as in luminous bacteria and fireflies. Luciferase is a protein that forms crystals in insect cells. SEQ ID NO: 20 shows the amino acid sequence of firefly luciferase, and SEQ ID NO: 21 shows the amino acid sequence of Renilla luciferase.
[0021] μNS is a crystalline nonstructural protein of reovirus. The amino acid sequence of μNS from reovirus is shown in SEQ ID NO:22.
[0022] Fusolin is a constituent protein of crystalline protein inclusion bodies formed by entomopoxviruses in host cells. SEQ ID NO: 23 shows the amino acid sequence of entomopoxvirus-derived Fusolin.
[0023] Crystalline inclusion protein A (CipA) is a constituent protein of the crystal protein inclusion body of the genus Photorhabdus. SEQ ID NO: 24 shows the amino acid sequence of CipA derived from Photorhabdus laumondii.
[0024] In this specification, one or more means, for example, 1 to 50, for example, 1 to 35, for example, 1 to 20, for example, 1 to 15, for example, 1 to 10, for example, 1 to 5.
[0025] As long as the crystalline protein has the ability to form crystals, it may be a mutant having a mutation in the above-mentioned cytoplasmic polyhedrin protein, nuclear polyhedrin protein, insecticidal protein, cathepsin B, luciferase, μNS, CipA, Fusolin, etc. More specifically, the crystalline protein may be a protein consisting of an amino acid sequence in which one or more amino acids have been deleted, substituted or added in the amino acid sequences set forth in the above-mentioned SEQ ID NOs: 1 to 2 and 18 to 24, for example.
[0026] Here, the target peptide may be, for example, a peptide whose three-dimensional structure is to be analyzed. As described below, the crystalline protein, which is a fusion protein of the above-mentioned crystalline protein and the target peptide, is expressed in a cell-free protein synthesis system to form a crystal, and the crystal of the crystalline protein is subjected to X-ray crystal structure analysis, thereby easily analyzing the three-dimensional structure of the target peptide.
[0027] In this case, the target peptide may be any peptide for which there is a need to analyze the three-dimensional structure. The length of the amino acids in the target peptide is preferably, for example, about 5 to 50 amino acids, from the viewpoint of enabling the crystalline protein to maintain its crystal-forming ability.
[0028] The most common method for crystallizing proteins is to purify the protein from cells and then crystallize it. This method requires more than two weeks to obtain crystals and requires a great deal of effort.
[0029] For example, in order to produce polyhedron crystals, a method was sometimes used in which cells were infected with baculovirus and polyhedron crystals were produced within the cells, but in this case, it took about two weeks to prepare the baculovirus.
[0030] On the other hand, in the case of the method for producing crystals using a cell-free protein synthesis system of the present embodiment, the time required for expressing and crystallizing a crystalline protein is about one day. Furthermore, according to the method for producing protein crystals of the present embodiment, the operation is very simple and requires little effort.
[0031] Furthermore, the amount of the cell-free protein synthesis system can be freely set. As described later in the Examples, for example, even when the amount of reaction solution in the cell-free protein synthesis system is about 22 μL, protein crystals can be obtained. The lower limit of the reaction solution volume in the cell-free protein synthesis system is preferably 15 μL or more, more preferably 18 μL or more, even more preferably 20 μL or more, and particularly preferably 22 μL or more. By having the reaction solution volume be equal to or more than the above lower limit, the shape of the protein crystals can be made more regular. The upper limit of the reaction solution volume in the cell-free protein synthesis system is not particularly limited, and can be a volume that can form protein crystals. The reaction solution volume can be, for example, 5 mL or less, 1 mL or less, 500 μL or less, 200 μL or less, 100 μL or less, 50 μL or less, or 30 μL or less.
[0032] When synthesizing a crystalline protein within a cell, it is necessary to synthesize the crystalline protein at a temperature and in an environment suitable for the proliferation and growth of the cell. On the other hand, when synthesizing a crystalline protein in a cell-free protein synthesis system, the temperature, environment, etc. can be appropriately set. For example, by synthesizing a crystalline protein using a cell-free protein synthesis system at a temperature lower than the general culture temperature of cells, the quality of the obtained crystals can be improved.
[0033] Furthermore, as described later in the Examples, by injecting the reaction solution of a cell-free protein synthesis system into a capillary, protein crystals can be obtained even if the amount of the reaction solution is 20 μL or less. When protein crystals are obtained using a capillary, the amount of the reaction solution injected into the capillary is preferably 5 μL or more, more preferably 12 μL or more, even more preferably 15 μL or more, and particularly preferably 18 μL or more. By making the amount of the reaction solution equal to or more than the above lower limit, the shape of the protein crystals can be made more regular. The upper limit of the amount of the reaction solution of the cell-free protein synthesis system to be injected into the capillary is not particularly limited, and can be any amount that can form protein crystals and can be held by the capillary. The amount of the reaction solution may be, for example, 100 μL or less, 50 μL or less, or 20 μL or less.
[0034] In the production method of this embodiment, in step (a), a nucleic acid encoding a crystalline protein is added to a protein synthesis system.
[0035] (nucleic acid) In this embodiment, the nucleic acid encoding the crystalline protein may be DNA or RNA. The base sequence of the nucleic acid encoding the protein may be one that has synonymous substitutions so that the expression of the crystalline protein is optimized in a cell-free protein synthesis system described below.
[0036] In this embodiment, the number of crystalline proteins expressed in the same cell-free protein synthesis system may be one or more. In this embodiment, the number of nucleic acids added to the cell-free protein synthesis system may be one or more.
[0037] The DNA sequence may have a promoter for binding RNA polymerase upstream of the sequence encoding the crystalline protein. The promoter may be one that has activity in a protein synthesis system, or may be an expression-inducible promoter whose activity can be induced by a drug or the like. The promoter is not particularly limited, and examples thereof include T3, T7, SP6 promoter, cytomegalovirus promoter (CMV promoter), CMV early enhancer / chicken beta actin (CAG promoter), and the like. An example of an expression-inducible promoter is a doxycycline-inducible promoter (TetO promoter), whose promoter activity can be artificially controlled, and the like.
[0038] The RNA may have a ribosome binding site upstream of the sequence encoding the crystalline protein, such as, but not limited to, the Shine-Dalgarno sequence, the Kozak sequence, the internal ribosome entry site (IRES), or any other sequence known to those skilled in the art.
[0039] In step (b) of this embodiment, the protein synthesis system is incubated for a predetermined time until the crystalline protein encoded by the added nucleic acid is expressed and the expressed protein completes the formation of crystals. Here, the predetermined time may be 10 minutes or more, 30 minutes or more, 1 hour or more, 3 hours or more, 6 hours or more, 12 hours or more, 24 hours or more, 32 hours or more, or 48 hours or more. The predetermined time may be 64 hours or less, 48 hours or less, 32 hours or less, 24 hours or less, 12 hours or less, 6 hours or less, 3 hours or less, 1 hour or less, or 30 minutes or less. The upper and lower limits of the predetermined time can be selected arbitrarily.
[0040] In step (b) of this embodiment, the temperature of the protein synthesis system may be, for example, 3° C. or higher, 4° C. or higher, 10° C. or higher, 15° C. or higher, or 20° C. or higher. In addition, the temperature may be, for example, 35° C. or lower, 30° C. or lower, 25° C. or lower, 20° C. or lower, 15° C. or lower, 10° C. or lower, or 5° C. or lower. The upper and lower temperature limits can be selected arbitrarily.
[0041] When the reaction solution of the cell-free protein synthesis system is incubated for a predetermined time, protein crystals are formed at the bottom of the vessel containing the reaction solution. The formed crystals can be easily collected by a procedure such as centrifugation.
[0042] (Cell-free protein synthesis system) In this embodiment, the protein synthesis system is a cell-free protein synthesis system. The cell-free protein synthesis system refers to a system in which proteins are synthesized in vitro from nucleic acid templates using ribosomes, transcription and translation factors, etc., which are derived from living cells or are artificially synthesized, rather than synthesizing proteins within cells.
[0043] The cell-free protein synthesis system of the present embodiment may be a synthesis system including a transcription process in addition to a translation process. When the nucleic acid encoding the protein capable of forming crystals of the present embodiment is DNA, it is necessary to synthesize RNA encoding the protein capable of forming crystals by transcribing the DNA.
[0044] The step of transcribing DNA may be included in step (b) of this embodiment. That is, the cell-free protein synthesis system of this embodiment may contain a factor that enables transcription. Examples of factors that enable transcription include, but are not limited to, RNA polymerase, nucleotides, and the like, and factors known to those skilled in the art can be used.
[0045] In addition, the above-mentioned process of transcribing RNA from DNA does not have to be included in the steps of this embodiment. That is, RNA may be synthesized in advance using DNA encoding a crystalline protein as a template, and the RNA may be added to the cell-free protein synthesis system of this embodiment. Also, instead of using DNA encoding a crystalline protein, artificially chemically synthesized RNA encoding a crystalline protein may be used.
[0046] The cell-free protein synthesis system is not particularly limited, and examples thereof include synthesis systems using cell extracts obtained from wheat germ, yeast, insect cells, cultured mammalian cells, rabbit reticulocytes, Escherichia coli, etc.; synthesis systems in which factors necessary for translation are reconstituted, etc. The cell-free protein synthesis system used in this embodiment is not limited to the above-mentioned method, and known methods can be used (for example, see JP 2019-083825 A).
[0047] The cell extract used in the cell-free protein synthesis system may contain factors involved in translation, such as tRNA, aminoacylated tRNA synthetase, translation initiation factors, translation elongation factors, and translation termination factors.
[0048] The efficiency of protein synthesis may be increased by continuously adding, for example, amino acids and energy molecules (ATP, GTP) to the cell extract. In addition, for example, energy regeneration systems, salts, creatine phosphate, enzymes, etc. may be added to the cell extract as necessary.
[0049] The synthesis system in which factors necessary for translation are reconstituted is not particularly limited, and for example, a known method can be used. (For example, Shimizu, Y. et al., Cell-free translation reconstituted with purified components, Nature Biotech., 19, 751-755, 2001). The reconstituted synthesis system may contain, for example, a translation initiation factor, a translation elongation factor, a termination factor, an aminoacyl-tRNA synthetase, a methionyl-tRNA formyltransferase, etc.
[0050] For example, the following operations may be performed using the cell-free protein synthesis system. As described above, factors that regulate translation may be added to the cell-free protein synthesis system as needed. In addition, the pH, salt concentration, etc. of the synthesis system may be changed as needed.
[0051] Furthermore, as described below, the target substance can be added to a cell-free protein synthesis system to cause the target substance to be encapsulated in the polyhedra.
[0052] Furthermore, by adding, for example, a non-natural amino acid or a radioactively labeled amino acid to a cell-free protein synthesis system, the non-natural amino acid or the radioactively labeled amino acid can be incorporated into the polyhedrin protein of the polyhedron.
[0053] Furthermore, compounds that are harmful or toxic to cells can also be added to the cell-free protein synthesis system.
[0054] In addition, by using a cell-free protein synthesis system, it is possible to synthesize a large amount of crystalline protein. As described above, for example, by adding a factor that enhances the efficiency of protein synthesis to the cell-free protein synthesis system, it is possible to synthesize a large amount of crystalline protein.
[0055] The above-mentioned crystalline protein may be one selected from the group consisting of the following (i), (ii), (iii) and (iv). (i) A protein consisting of the amino acid sequence set forth in SEQ ID NO: 1, or a protein consisting of the amino acid sequence set forth in SEQ ID NO: 1 in which one or more amino acids have been deleted, substituted or added, and having the ability to form polyhedra. (ii) A protein consisting of the amino acid sequence set forth in SEQ ID NO: 2, or a protein consisting of the amino acid sequence set forth in SEQ ID NO: 2 in which one or more amino acids have been deleted, substituted or added, and having crystal-forming ability. (iii) A protein consisting of the amino acid sequence set forth in SEQ ID NO: 18, or a protein consisting of the amino acid sequence set forth in SEQ ID NO: 18 in which one or more amino acids have been deleted, substituted or added, and having crystal-forming ability. (iv) A fusion protein in which the 70th to 77th amino acids in the amino acid sequence set forth in SEQ ID NO: 1 are replaced with a target peptide and has the ability to form polyhedra, or a fusion protein in which one or more amino acids are deleted, substituted or added and has the ability to form polyhedra. These will be explained in detail.
[0056] In this specification, one or more means, for example, 1 to 50, for example, 1 to 35, for example, 1 to 20, for example, 1 to 15, for example, 1 to 10, for example, 1 to 5.
[0057] (First embodiment) The crystalline protein may be: (i) a crystalline protein; (i) A protein consisting of the amino acid sequence set forth in SEQ ID NO: 1, or a protein consisting of the amino acid sequence set forth in SEQ ID NO: 1 in which one or more amino acids have been deleted, substituted or added, and having the ability to form polyhedra.
[0058] The protein consisting of the amino acid sequence set forth in SEQ ID NO: 1 is a wild-type polyhedrin protein expressed by the cytoplasmic polyhedrosis virus (CPV) that infects silkworms. The wild-type polyhedrin protein has the ability to form polyhedra by spontaneous self-accumulation.
[0059] As described later in the Examples, polyhedral protein crystals can be produced by expressing the crystalline protein (i) in the above-mentioned cell-free protein synthesis system and incubating the cell-free protein synthesis system.
[0060] Second embodiment The crystalline protein may be: (ii) (ii) A protein consisting of the amino acid sequence set forth in SEQ ID NO: 2, or a protein consisting of the amino acid sequence set forth in SEQ ID NO: 2 in which one or more amino acids have been deleted, substituted or added, and having the ability to form polyhedra.
[0061] The protein consisting of the amino acid sequence set forth in SEQ ID NO:2 is a wild-type polyhedrin protein expressed by the nucleopolyhedrovirus (NPV) that infects the moth Autographa californica. This wild-type polyhedrin protein has the crystal-forming ability to form protein crystals by spontaneous self-accumulation.
[0062] Polyhedral protein crystals can be produced by expressing the crystalline protein (ii) above in the above-mentioned cell-free protein synthesis system and incubating the cell-free protein synthesis system.
[0063] Third embodiment The crystalline protein may be (iii) below: (iii) A protein consisting of the amino acid sequence set forth in SEQ ID NO: 18, or a protein consisting of the amino acid sequence set forth in SEQ ID NO: 18 in which one or more amino acids have been deleted, substituted or added, and having crystal-forming ability.
[0064] The protein consisting of the amino acid sequence set forth in SEQ ID NO: 18 is the Cry3A protein produced by Bacillus thuringiensis. The wild-type Cry3A protein has the crystal-forming ability to form protein crystals by spontaneous self-accumulation.
[0065] As described later in the Examples, the crystalline protein (iii) above is expressed in the above-mentioned cell-free protein synthesis system, and the cell-free protein synthesis system is then incubated to produce crystals of the crystalline protein.
[0066] (Fourth embodiment) The crystalline protein may be: (iv) (iv) A fusion protein in which the 70th to 77th amino acids in the amino acid sequence set forth in SEQ ID NO: 1 are replaced with a target peptide and has the ability to form polyhedra, or a fusion protein in which one or more amino acids are deleted, substituted or added and has the ability to form polyhedra.
[0067] By analyzing the crystal structure of the polyhedron obtained by crystallizing the fusion protein of this embodiment, the crystal structure of the target peptide can be easily analyzed.
[0068] Furthermore, the size of the polyhedral crystals can be controlled by appropriately designing the amino acid sequence of the target peptide.
[0069] The number of amino acids in the amino acid sequence of the target peptide may be, for example, 5 to 25 residues, 7 to 23 residues, or 9 to 18 residues.
[0070] As described later in the Examples, examples of the fusion protein of this embodiment include fusion proteins consisting of the amino acid sequences shown in SEQ ID NOs: 8 to 10, 12, and 15. The amino acid sequences of these fusion proteins will be described in detail.
[0071] The fusion protein of SEQ ID NO:8 is a fusion protein in which the 70th to 77th amino acids of the amino acid sequence of SEQ ID NO:1 are replaced with a target peptide consisting of the amino acid sequence of SEQ ID NO:7.
[0072] The fusion protein of SEQ ID NO:9 is a fusion protein in which two amino acid residues are inserted on the N-terminus side of the target peptide and one amino acid residue is inserted on the C-terminus side of the target peptide in the fusion protein of SEQ ID NO:8.
[0073] The fusion protein of SEQ ID NO:10 is a fusion protein in which three amino acid residues are inserted on the N-terminus side of the target peptide and three amino acid residues are inserted on the C-terminus side of the target peptide in the fusion protein of SEQ ID NO:8.
[0074] The fusion protein of SEQ ID NO:12 is a fusion protein in which 4 amino acid residues are inserted on the N-terminus side of the target peptide and 4 amino acid residues are inserted on the C-terminus side of the target peptide in the fusion protein of SEQ ID NO:8.
[0075] The fusion protein of SEQ ID NO:15 is a fusion protein in which 4 amino acid residues are inserted on the N-terminus side of the target peptide and 4 amino acid residues are inserted on the C-terminus side of the target peptide in the fusion protein of SEQ ID NO:8.
[0076] As described below in the Examples, polyhedron crystals formed from the protein of SEQ ID NO:12 are approximately 400 nm in size, which is small compared to the size of crystals formed from the wild-type polyhedrin protein.
[0077] Fifth embodiment In one embodiment, the present invention provides a method for producing protein crystals, wherein the crystalline protein is (i) or (iv), and in the step (a), a nucleic acid encoding a fusion protein in which a target peptide is bound to the C-terminus of the amino acid sequence set forth in SEQ ID NO: 4, or the amino acid sequence set forth in SEQ ID NO: in which one or more amino acids have been deleted, substituted or added, is further added to the cell-free protein synthesis system.
[0078] The amino acid sequence set forth in SEQ ID NO:4 is the H1 α-helical region of the wild-type cytoplasmic polyhedrin protein. In this embodiment, when a fusion protein and a protein capable of forming polyhedra are expressed in a cell-free protein synthesis system, these proteins form polyhedra, and the fusion protein can form part of the polyhedra.
[0079] When the target peptide bound to the C-terminus of the fusion protein binds and the protein capable of forming polyhedra forms polyhedra, the target peptide is encapsulated in the polyhedra. As described later in the Examples, when the target peptide is GFP, the polyhedra can encapsulate GFP.
[0080] The sequence of the target peptide is not particularly limited. The number of residues in the amino acid sequence of the target peptide is preferably 3 to 500 residues, more preferably 3 to 400 residues, and even more preferably 3 to 300 residues.
[0081] Sixth embodiment The crystalline protein may be a modified polyhedrin protein, which is a protein of (v) or (vi) below, in which at least a portion of the amino acid sequence is deleted and which has the ability to form polyhedra. (v) wild-type polyhedrin protein (vi) A protein having an amino acid sequence in which one or more amino acids have been deleted, substituted or added in the amino acid sequence of a wild-type polyhedrin protein and has the ability to form polyhedra. The wild-type polyhedrin protein may be a wild-type polyhedrin protein expressed by CPV or a wild-type polyhedrin protein expressed by NPV. More specifically, the wild-type polyhedrin protein may be, for example, a protein consisting of the amino acid sequence set forth in SEQ ID NO:1, or a protein consisting of the amino acid sequence set forth in SEQ ID NO:2.
[0082] The polyhedra formed by crystallizing the modified polyhedrin protein of this embodiment have internal spaces. This makes it easy to encapsulate larger molecules that were previously difficult to encapsulate. In this specification, the term "peptide" encompasses proteins.
[0083] In this embodiment, the modified polyhedrin protein may be one in which at least a portion of the amino acid sequence of the wild-type polyhedrin protein has been deleted.
[0084] Furthermore, in this embodiment, the modified polyhedrin protein may be an amino acid sequence in which one or more amino acids have been deleted, substituted or added in the amino acid sequence of the wild-type polyhedrin protein, and may be a protein having the ability to form polyhedra in which at least a portion of the amino acid sequence has been deleted.
[0085] The total length of at least a portion of the deleted amino acid sequence may be 30 or more amino acids, 35 or more amino acids, or 40 or more amino acids. If more amino acids can be deleted while maintaining the ability to form polyhedra, the space inside the polyhedra can be made larger.
[0086] The upper limit of the total length of at least a portion of the deleted amino acid sequence may be any length that enables the modified polyhedrin protein to maintain its ability to form polyhedra, and may be, for example, 100 amino acids, for example, 80 amino acids, or for example, 50 amino acids.
[0087] Furthermore, the deleted amino acid sequence may be at one position or at two or more positions, so long as the polyhedron-forming ability is maintained. That is, the deleted amino acid sequence may be at one continuous amino acid sequence region or at two or more separate amino acid sequence regions in the amino acid sequence of the wild-type polyhedrin protein from which the modified polyhedrin protein is derived.
[0088] The wild-type polyhedrin protein on which the modified polyhedrin protein of this embodiment is based is not particularly limited as long as it is a polyhedron-forming polyhedrin protein, and may be, for example, a protein consisting of the amino acid sequence set forth in SEQ ID NO:1.
[0089] More specific examples of the modified polyhedrin protein of this embodiment include, for example, a protein consisting of the amino acid sequence set forth in SEQ ID NO: 3, or a protein consisting of an amino acid sequence in which one or more amino acids have been deleted, substituted or added in the amino acid sequence set forth in SEQ ID NO: 3 and having the ability to form polyhedra. The amino acid sequence shown in SEQ ID NO:3 is a sequence in which 38 residues from the 67th alanine residue to the 104th alanine residue in the amino acid sequence shown in SEQ ID NO:1 are deleted.
[0090] Seventh embodiment The above-mentioned crystalline protein may be a fusion protein having a target peptide inserted between the 66th and 67th amino acids of the amino acid sequence set forth in SEQ ID NO:3 and having the ability to form polyhedra, or a fusion protein having an amino acid sequence in which one or more amino acids have been deleted, substituted or added in the fusion protein and having the ability to form polyhedra.
[0091] The fusion protein of this embodiment is a fusion protein of the above-mentioned modified polyhedrin protein and a target peptide. In addition, in the fusion protein of this embodiment, the target peptide is inserted into a region in which some amino acids have been deleted from the wild-type polyhedrin protein from which the modified polyhedrin protein is derived.
[0092] The target peptide is regularly arranged inside the polyhedron obtained by crystallizing the fusion protein of this embodiment, so that the crystal structure of the target peptide can be easily analyzed using the fusion protein of this embodiment.
[0093] Eighth embodiment The above-mentioned crystalline protein is a protein having a moiety containing an amino acid capable of coordinating a metal atom and capable of forming a polyhedron, and the target molecule may be a substance containing a metal atom. The moiety containing an amino acid capable of coordinating a metal atom may be located at the C-terminus of the above-mentioned protein.
[0094] Examples of amino acids having a coordinating ability to a metal atom include histidine, glutamic acid, aspartic acid, cysteine, serine, etc. Examples of sites containing an amino acid having a coordinating ability to a metal atom include sites containing one or more amino acids selected from the above-mentioned amino acids, such as a site of about six consecutive histidines, a site in which an amino acid having a coordinating ability to a metal atom is exposed in the space inside a polyhedron crystal, and a site in which an amino acid having a coordinating ability to a metal atom is exposed on the surface of a polyhedron crystal.
[0095] Ninth embodiment The cell-free protein synthesis system may contain a target molecule having a molecular weight of 10 to 100,000.
[0096] By expressing the above-mentioned crystalline protein in a cell-free protein synthesis system containing a target molecule, the crystals of the above-mentioned crystalline protein can encapsulate the target molecule.
[0097] As described above, by modifying the amino acid sequence of a protein capable of forming polyhedra, the target molecule can also be made to bind to the surface of the polyhedron.
[0098] (target molecule) The molecular weight of the target molecule is preferably 10 to 100000, more preferably 10 to 60000, and even more preferably 10 to 30000. When the molecular weight of the target molecule is within the above range, the target molecule is easily encapsulated in the polyhedron.
[0099] The target molecule is not particularly limited, and examples thereof include inorganic substances, organic substances, substances containing metal atoms, etc. The organic substance may be, for example, a peptide, a protein, fluorescein, etc.
[0100] Examples of substances containing metal atoms include metal complexes, metal atom-containing proteins, and metal atom-containing organic compounds.
[0101] Examples of metal complexes include substances containing one or more metal atoms selected from copper, nickel, zinc, cobalt, manganese, iron, ruthenium, rhenium, etc., such as Mn(CO)5Br, Mn(CO)5Cl, Ru2(CO)6Cl4, Fe3(CO) 12 , Re(CO)5Cl, etc.
[0102] Metal atom-containing proteins include hemoproteins such as cytochrome P450 and hemoglobin, and non-heme proteins such as superoxide dismutase (SOD) and alcohol dehydrogenase.
[0103] Examples of the metal atom-containing organic compound include protoporphyrin and chlorophyll.
[0104] [Fusion protein] In one embodiment, the present invention provides a fusion protein having polyhedron-forming ability, in which the amino acid sequence from the 70th to the 77th amino acid in the amino acid sequence set forth in SEQ ID NO: 1 is replaced by a target peptide, or a fusion protein having polyhedron-forming ability, which consists of an amino acid sequence in which one or more amino acids have been deleted, substituted or added in the fusion protein.
[0105] The fusion protein of this embodiment is the same as the fusion protein described above in the third embodiment of the method for producing crystals.
[0106] By analyzing the crystal structure of the polyhedron obtained by crystallizing the fusion protein of this embodiment, the crystal structure of the target peptide can be easily analyzed.
[0107] Furthermore, the size of the polyhedral crystals can be controlled by appropriately designing the amino acid sequence of the target peptide.
[0108] [Polyhedron] In one embodiment, the present invention provides a polyhedron formed by crystallizing the fusion protein described above in [Fusion Protein]. When the fusion protein of this embodiment is expressed in a cell-free protein synthesis system or in a cell as described above, the fusion protein forms a polyhedron crystal.
[0109] [Polyhedrin-target molecule complex] In one embodiment, the present invention provides a polyhedron-target molecule complex in which a target molecule is encapsulated in the crystal structure of the polyhedron described above in [Polyhedron]. When a polyhedron is formed from the above-mentioned fusion protein, a target molecule can be contacted with the fusion protein to obtain a polyhedron-target molecule complex in which a target molecule is encapsulated in the crystal structure of the polyhedron.
[0110] [Nucleic acid] In one embodiment, the present invention provides a nucleic acid encoding the fusion protein described above in [Fusion Protein]. In this embodiment, the nucleic acid may be RNA or DNA.
[0111] [Cell-free crystal production kit] In one embodiment, the present invention provides a kit for cell-free crystal production, comprising a nucleic acid encoding a crystalline protein and a reagent for a cell-free protein synthesis system.
[0112] By using the reagents included in the kit of this embodiment, a cell-free protein synthesis system can be easily prepared. Examples of the cell-free protein synthesis system include those described above in the [Production method]. The cell-free protein synthesis system may be a synthesis system using a cell extract, or a synthesis system in which factors necessary for translation are reconstituted.
[0113] When the cell-free protein synthesis system is a synthesis system using a cell extract, the reagents of the cell-free protein synthesis system included in the kit may contain a cell extract. The biological species of cells from which the cell extract is derived is not particularly limited, and examples thereof include those mentioned above in the [Production method].
[0114] When the cell-free protein synthesis system is a synthesis system in which factors necessary for translation are reconstituted, the kit may contain the factors necessary for translation. The biological species from which the factors necessary for translation are derived is not particularly limited.
[0115] The kit of this embodiment may contain factors that enhance the efficiency of protein synthesis, such as amino acids, energy molecules, etc. Examples of factors that enhance the efficiency of protein synthesis include those mentioned above in the [Production method].
[0116] The nucleic acid contained in the kit of this embodiment may be RNA or DNA. The sequence of the nucleic acid encoding the above-mentioned protein may be one that has synonymous substitution so as to optimize the expression of the protein in a cell-free protein synthesis system.
[0117] When the nucleic acid is DNA, the DNA may be linear or circular. The circular DNA may be, for example, an expression vector such as a plasmid. The plasmid may have a promoter or a ribosome binding site upstream of the DNA sequence encoding the above-mentioned protein.
[0118] The kit of this embodiment may contain factors necessary for transcription. Examples of factors necessary for transcription include the factors mentioned above in the [Production method]. When the nucleic acid encoding the protein is DNA, RNA can be synthesized by transcription using the factors necessary for transcription included in the kit of this embodiment.
[0119] (First embodiment) In the kit of this embodiment, the crystalline protein may be any of the proteins (A) to (C) below. (A) Cytoplasmic polyhedrin protein, nuclear polyhedrin protein, insecticidal protein, cathepsin B, luciferase, reovirus nonstructural protein (μNS), CipA, or Fusolin protein (B) A protein having an amino acid sequence in which one or more amino acids have been deleted, substituted or added in the amino acid sequence of the protein (A) and having crystal-forming ability. (C) A fusion protein of the protein (A) or (B) with a target peptide.
[0120] For example, by adding the nucleic acid encoding the above-mentioned crystalline protein included in the kit of this embodiment to the cell-free protein synthesis system included in the kit of this embodiment, the crystalline protein can be synthesized and protein crystals can be easily produced.
[0121] Second embodiment In the kit of this embodiment, the crystalline protein may be one selected from the group consisting of the following (i), (ii), (iii) and (iv). (i) A protein consisting of the amino acid sequence set forth in SEQ ID NO: 1, or a protein consisting of the amino acid sequence set forth in SEQ ID NO: 1 in which one or more amino acids have been deleted, substituted or added, and having the ability to form polyhedra. (ii) A protein consisting of the amino acid sequence set forth in SEQ ID NO: 2, or a protein consisting of the amino acid sequence set forth in SEQ ID NO: 2 in which one or more amino acids have been deleted, substituted or added, and having the ability to form polyhedra. (iii) A protein consisting of the amino acid sequence set forth in SEQ ID NO: 18, or a protein consisting of the amino acid sequence set forth in SEQ ID NO: 18 in which one or more amino acids have been deleted, substituted or added, and having crystal-forming ability. (iv) A fusion protein having polyhedron-forming ability, in which the 70th to 77th amino acids in the amino acid sequence set forth in SEQ ID NO: 1 are replaced with a target peptide, or a protein having polyhedron-forming ability, which is an amino acid sequence in which one or more amino acids are deleted, substituted or added in the fusion protein.
[0122] For example, by adding the nucleic acid encoding the above-mentioned crystalline protein included in the kit of this embodiment to the cell-free protein synthesis system included in the kit of this embodiment, the crystalline protein can be synthesized and protein crystals can be easily produced.
[0123] Third embodiment When the kit of this embodiment contains a nucleic acid encoding the above-mentioned (i) or (iv), the kit of this embodiment may further contain a nucleic acid encoding a fusion protein in which a target peptide is bound to the C-terminus of the amino acid sequence set forth in SEQ ID NO: 4, or the amino acid sequence set forth in SEQ ID NO: 4 in which one or more amino acids have been deleted, substituted or added.
[0124] By adding the nucleic acid provided in this embodiment to a cell-free protein synthesis system provided in the kit of this embodiment, a protein having polyhedron-forming ability and a fusion protein are expressed, which form polyhedra, and the fusion protein can form part of the polyhedron.
[0125] The polyhedron crystals produced by the above-mentioned production method can be collected by, for example, centrifuging the reaction mixture of the translation reaction.
[0126] Polyhedron crystals can be stored in solutions such as distilled water, buffered saline, or distilled water containing antibiotics.
[0127] Since the target molecule encapsulated in the polyhedron is protected by the polyhedron, by encapsulating the target molecule in a polyhedron-target molecule complex, the stability against ultraviolet light, heat, drying, immersion in a urea solution, immersion in an acid, immersion in a solution containing a surfactant, etc. can be improved.
[0128] In addition, since the polyhedron-targeting molecule complex has cell affinity (low biotoxicity), it can be applied to the storage and controlled release of metal-containing drugs and to the control of reactions of small molecules in vivo.
[0129] The reaction control of a small molecule includes capture of a small molecule, release of a small molecule, synthesis of a small molecule, decomposition of a small molecule, and the like.
[0130] Furthermore, for example, the pH of a solution containing polyhedra can be changed to, for example, 10 or higher to enable controlled release of the target molecule. In addition to changes in pH, the target molecule that releases an active substance upon light irradiation, temperature change, or addition of an active molecule can be encapsulated in the complex to enable controlled release of the active substance upon light irradiation, temperature change, or addition of an active molecule. An example of a target molecule that releases a substance upon light irradiation is Mn(CO)5Br. Mn(CO)5Br releases CO upon light irradiation.
[0131] It is known that gas molecules such as CO, NO, and O2 are closely involved in cerebral infarction, Alzheimer's disease, carcinogenesis, and liver disease. These gas molecules penetrate into cells and affect neurotransmission, transcription factor activity, and other conditions.
[0132] Previously, it has been reported that CO release materials were supported on polymers, gels, and porous materials, and that CO release was achieved at room temperature and pressure, or in water, but there are issues with the materials being biotoxic and the synthesis process being complicated, etc. In contrast, polyhedron-target molecule complexes have cell affinity and are easy to manufacture.
[0133] For example, polyhedra encapsulating gas molecule-releasing materials such as CO, NO, and O2 as target molecules can provide new materials that have cell affinity and can controllably release gas molecules. By incorporating such materials into evaluation systems constructed using iPS cells or ES cells, they can be used in the development of medicines for cerebral infarction, Alzheimer's disease, carcinogenesis, liver disease, and other conditions.
[0134] According to the present invention, as described above, polyhedrin protein can be expressed and polyhedra can be crystallized in an extremely small amount of reaction solution of about 50 μL, which allows the operations from polyhedrin protein expression to crystallization to be carried out in 24-well, 96-well, or 384-well plates.
[0135] Because of the small-scale and simultaneous handling of many samples as described above, it is possible to use the crystallized polyhedra to verify the effects of drugs with high throughput. For example, it is possible to efficiently screen for active drugs by encapsulating a target substance in the polyhedra and allowing a library of drug candidates to act on the target substance encapsulated in the polyhedra under appropriate conditions. EXAMPLES
[0136] The present invention will be described below with reference to examples, but the present invention is not limited to the following examples.
[0137] [Experimental Example 1] (Crystallization of wild-type polyhedrin using a cell-free protein synthesis system) Wild-type polyhedrin of CPV was expressed in a wheat germ cell-free protein synthesis system, and polyhedral crystals were formed.
[0138] The wheat germ cell-free protein synthesis system used was SUB-AMIX SGC, WEPRO 9240 and pEU-E01-MCS vector, both manufactured by Cell Free Sciences.
[0139] First, cDNA encoding the wild-type polyhedrin protein shown in SEQ ID NO: 1 was inserted into the pEU-E01-MCS vector to obtain an expression vector. 2 μg of the obtained expression vector was prepared and added to a Transcription Premix LM tube, which was then incubated at 37° C. for 6 hours to synthesize mRNA and obtain a transcription reaction solution.
[0140] The transcription reaction solution was placed at the bottom of the well containing SUB-AMIX SGC to form a layer in the well.Then, the well was incubated at 15°C for 20 hours to carry out the translation reaction and synthesize wild-type polyhedrin.
[0141] One day after the start of the translation reaction, the crystals formed at the bottom of the well were observed. The results are shown in Figure 1. Figure 1 is a photograph of wild-type polyhedrin crystals obtained by the cell-free protein synthesis system. As a result, it was revealed that the cell-free protein synthesis system allows crystals to be obtained in just one day by the simple procedures described above.
[0142] The obtained crystals were then observed by scanning electron microscope (SEM). The results are shown in Figure 2. In addition, the temperature during the translation reaction was changed to 20°C, and crystals were similarly prepared. The obtained crystals were observed by SEM. The results are shown in Figure 3.
[0143] As a result, the size of the crystals obtained by carrying out the translation reaction at 15° C. and 20° C. was 0.5 μm to 1.5 μm. Furthermore, no significant differences were observed in the size and shape of the crystals obtained when the translation reaction was carried out at 15° C. and when the translation reaction was carried out at 20° C.
[0144] The most common method for crystallizing proteins is to purify the protein from cells and then crystallize it. This method requires more than two weeks to obtain crystals and requires a great deal of effort.
[0145] In some cases, a method of producing polyhedron crystals by infecting cells with baculovirus and producing polyhedron crystals within the cells was used, but in this case, it took about two weeks to prepare the baculovirus.
[0146] On the other hand, according to the method for producing crystals of the present invention, as exemplified in Experimental Example 1, it has become clear that crystallization can be achieved in a short period of time, about one day, by a very simple method.
[0147] [Experimental Example 2] (X-ray structural analysis of crystals obtained using a cell-free protein synthesis system) The three-dimensional structure of the wild-type polyhedrin crystal of CPV obtained in Experimental Example 1 was analyzed by X-ray structural analysis. The resolution was set to 2.5 Å. The results are shown in FIG.
[0148] As a result, no significant difference was found between the three-dimensional structure of the wild-type polyhedrin crystals obtained by the cell-free protein synthesis system and that of the wild-type polyhedrin crystals synthesized by the conventional method, i.e., in cells. Furthermore, the three-dimensional structure could be analyzed even when the resolution was set to 1.70 Å.
[0149] [Experimental Example 3] (Crystallization conditions for crystals obtained by cell-free protein synthesis system) The amount of the solution after the translation reaction obtained in Experimental Example 1 was adjusted to examine the amount of solution that would give well-formed crystals of wild-type polyhedrin of CPV.
[0150] Specifically, the morphology of the crystals obtained from the solutions (220 μL, 55 μL, 22 μL) after the translation reaction obtained in Experimental Example 1 was observed by optical microscope or SEM. The results are shown in Figures 5A to 5C. Figure 5A is an SEM image of the crystals obtained from 220 μL and 55 μL solutions. Figure 5B is an optical microscope image of the crystals obtained from 22 μL solution, and Figure 5C is an SEM image of the crystals obtained from 22 μL solution.
[0151] As a result, crystals having a regular cubic shape were obtained from 220 μL of the solution after the translation reaction, and also from 55 μL and 22 μL of the solution after the translation reaction.
[0152] [Experimental Example 4] (Crystallization of polyhedrin fragment-GFP fusion protein) A fusion protein consisting of a fragment of CPV polyhedrin protein fused with GFP was coexpressed with wild-type CPV polyhedrin protein in a cell-free protein synthesis system, and polyhedra encapsulating GFP were produced.
[0153] As in Experimental Example 1, a cDNA encoding the GFP fusion protein represented by sequence number 5 and a cDNA encoding the wild-type polyhedrin protein represented by sequence number 1 were inserted into the pEU-E01-MCS vector to prepare expression vectors.
[0154] Crystals were produced by expressing the protein in a cell-free protein synthesis system in the same manner as in Experimental Example 1. The fusion protein shown in SEQ ID NO:5 is a protein in which GFP protein is fused to the C-terminus of the H1 α-helix located at the N-terminus of the wild-type polyhedrin protein.
[0155] The crystals formed in the solution after the translation reaction were observed. The results are shown in Figure 6. Figure 6A is a fluorescent image of GFP taken by irradiating the crystals with excitation light. Figure 6B is a superimposition of the bright-field image and fluorescent image of the crystals.
[0156] As a result, it was revealed that polyhedral crystals containing GFP were obtained.
[0157] [Experimental Example 5] (Crystallization of polyhedra containing fluorescein) Wild-type polyhedrin protein of CPV was expressed in a cell-free protein synthesis system containing fluorescein, and polyhedra containing fluorescein were crystallized.
[0158] The expression vector for expressing the wild-type polyhedrin protein obtained in Experimental Example 1 and fluorescein were added to a cell-free protein synthesis system to express the wild-type polyhedrin protein. The resulting crystals were observed. The results are shown in Figure 7.
[0159] Figure 7 shows a fluorescent image of polyhedral crystals encapsulating fluorescein, irradiated with excitation light, and revealed that polyhedral crystals encapsulating fluorescein were obtained.
[0160] [Experimental Example 6] (Crystallization of mutant polyhedrin proteins) Four mutant polyhedrin proteins, in which the amino acid sequence of L1 of wild-type CPV polyhedrin protein or a part of L1 was replaced with the following peptides, were expressed in a cell-free protein synthesis system and crystals were prepared. Crystals were also prepared in a capillary using a smaller amount of mutant polyhedrin protein solution.
[0161] Residues 70 to 77 of the wild-type polyhedrin protein consisting of the amino acid sequence shown in SEQ ID NO: 1 are called L1 (loop region) and consist of the amino acid sequence shown in SEQ ID NO: 6. The amino acid sequence near L1 was replaced with the following peptides, etc., as follows.
[0162] The amino acid sequence of residues 70 to 77 of the wild-type polyhedrin protein shown in SEQ ID NO: 1 was replaced with the CLN025 peptide shown in SEQ ID NO: 7 to design a mutant polyhedrin protein (ΔL1-CLN-1) shown in SEQ ID NO: 8. A schematic diagram of the three-dimensional structure of the mutant polyhedrin protein near the CLN025 peptide is shown in Figure 8A.
[0163] A mutant polyhedrin protein (ΔL1-CLN-2) represented by SEQ ID NO: 9 was designed in which two amino acid residues were inserted at the N-terminus of the target peptide and one amino acid residue was inserted at the C-terminus of the target peptide in the mutant polyhedrin protein represented by SEQ ID NO: 8. It can also be said that the amino acid sequence of ΔL1-CLN-2 is obtained by substituting the amino acid sequence of residues 72 to 76 of the wild-type polyhedrin protein shown in SEQ ID NO:1 with the CLN025 peptide shown in SEQ ID NO:7. A schematic diagram of the three-dimensional structure of this mutant polyhedrin protein near the CLN025 peptide is shown in FIG. 8B.
[0164] A mutant polyhedrin protein (ΔL1-CLN-3) represented by SEQ ID NO: 10 was designed in which three amino acid residues were inserted at the N-terminus of the target peptide and three amino acid residues were inserted at the C-terminus of the target peptide in the mutant polyhedrin protein represented by SEQ ID NO: 8. It can also be said that the amino acid sequence of ΔL1-CLN-3 is one in which the amino acid sequence of residues 73 to 74 of the wild-type polyhedrin protein shown in SEQ ID NO:1 is replaced with the CLN025 peptide shown in SEQ ID NO:7. A schematic diagram of the three-dimensional structure of this mutant polyhedrin protein near the CLN025 peptide is shown in FIG. 8C.
[0165] A mutant polyhedrin protein (ΔL1-CLN-f) represented by SEQ ID NO: 12 was designed in which 4 amino acid residues were inserted at the N-terminus of the target peptide and 4 amino acid residues were inserted at the C-terminus of the target peptide in the mutant polyhedrin protein represented by SEQ ID NO: 8. A 4-residue peptide represented by SEQ ID NO: 13 is linked to the N-terminus and C-terminus of the CLN025 peptide. The 4-residue peptide represented by SEQ ID NO: 13 has a high degree of conformational freedom. It can also be said that the amino acid sequence of ΔL1-CLN-f is one in which the amino acid sequence of residues 70 to 77 of the wild-type polyhedrin protein represented by SEQ ID NO: 1 is replaced with a peptide consisting of the amino acid sequence represented by SEQ ID NO: 11. A schematic diagram of the three-dimensional structure of this mutant polyhedrin protein near the CLN025 peptide is shown in FIG. 8D.
[0166] A mutant polyhedrin protein (ΔL1-CLN-r) represented by SEQ ID NO: 15 was designed in which 4 amino acid residues were inserted at the N-terminus of the target peptide and 4 amino acid residues were inserted at the C-terminus of the target peptide in the mutant polyhedrin protein represented by SEQ ID NO: 8. A 4-residue peptide represented by SEQ ID NO: 16 is linked to the N-terminus and C-terminus of the CLN025 peptide. The 4-residue peptide represented by SEQ ID NO: 16 has a low degree of freedom in its three-dimensional structure. It can also be said that the amino acid sequence of ΔL1-CLN-r is one in which the amino acid sequence of residues 70 to 77 of the wild-type polyhedrin protein represented by SEQ ID NO: 1 is replaced with a peptide consisting of the amino acid sequence represented by SEQ ID NO: 14. A schematic diagram of the three-dimensional structure of this mutant polyhedrin protein near the CLN025 peptide is shown in FIG. 8D.
[0167] Each of ΔL1-CLN-1, ΔL1-CLN-2, ΔL1-CLN-3, ΔL1-CLN-f, and ΔL1-CLN-r was expressed in a cell-free protein synthesis system, crystals were produced, and the obtained crystals were observed in the same manner as in Experimental Example 1. The results are shown in Figures 9 and 10.
[0168] The crystals were then condensed into cubic crystals, and the crystals were then condensed into cubic crystals.
[0169] Figure 10 is a histogram showing the side lengths of the resulting cubic crystals. The average length of each crystal side was less than 500 nm.
[0170] In addition, Δ3, a mutant polyhedrin protein lacking three amino acid residues (G192, S193, A194) as shown in SEQ ID NO: 17, was expressed in a cell-free protein synthesis system. When 18 μL of the cell-free protein synthesis system solution was injected into the capillary, crystals were obtained. The obtained crystals were observed using a microscope.
[0171] Figure 11A is a photograph of the capillary used, and Figure 11B is a bright-field image of the crystals obtained. When producing crystals using a capillary, crystals can be produced from a smaller amount of reaction solution, and the crystals in the capillary can be used efficiently.
[0172] [Experimental Example 7] (Identification of mutant polyhedrin proteins) The crystals obtained in Experimental Example 6 were analyzed by mass spectrometry and SDS-PAGE to confirm whether the obtained crystals were mutant polyhedrin proteins. In addition, polyhedral crystals obtained by expressing wild-type polyhedrin protein (WT-PhC) in Sf9 cells were also analyzed as a control.
[0173] In mass spectrometry, the obtained crystals were analyzed by MALDI-TOF-MS. The results of mass spectrometry are shown in FIG. 12. In FIG. 12, Calc. indicates the molecular weight calculated from the amino acid sequence, and Obs. indicates the mass estimated from the results of mass spectrometry. As a result, it was revealed that the obtained crystals were the mutant polyhedrin proteins shown in Experimental Example 6.
[0174] In SDS-PAGE, the obtained crystals were solubilized and electrophoresed. The results of SDS-PAGE are shown in Figure 13. As a result, it was revealed that the obtained crystals were the mutant polyhedrin proteins shown in Experimental Example 6.
[0175] [Experimental Example 8] (X-ray diffraction of mutant polyhedrin protein) The crystal obtained in Experimental Example 6 was irradiated with X-rays and analyzed for X-ray diffraction.
[0176] The solution after the translation reaction containing the polyhedron crystals in Experimental Example 6 was centrifuged, and the precipitated crystals were placed in a 50% PBS / ethylene glycol solution. The solution containing the crystals was placed on a mesh, and the numerous crystals on the mesh were irradiated with X-rays to observe the diffraction of the X-rays.
[0177] As a result, when X-rays were irradiated onto the crystals of ΔL1-CLN-3 and ΔL1-CLN-f, X-ray diffraction was frequently detected, whereas X-ray diffraction was not detected for the crystals of ΔL1-CLN-1 and ΔL1-CLN-r. X-ray diffraction was detected particularly frequently for the crystals of ΔL1-CLN-f. This result revealed that the crystals of ΔL1-CLN-f have a high degree of orientation. It was also suggested that structural analysis methods other than X-ray structural analysis could be applied to the crystals of ΔL1-CLN-f.
[0178] [Experimental Example 9] (Crystallization of Cry3A protein) In the same manner as in Experimental Example 1, the Cry3A protein represented by SEQ ID NO: 18 was expressed using a wheat germ cell-free protein synthesis system, and the resulting protein solution was kept at 4° C. or 20° C. to form crystals. The resulting crystals were observed using an optical microscope or a scanning electron microscope.
[0179] Fig. 14A is an optical microscope image of the crystals grown at 20° C., and Fig. 14B is an optical microscope image of the crystals grown at 4° C. Fig. 14C is an SEM image of the crystals grown at 20° C., and Fig. 14D is an SEM image of the crystals grown at 4° C. It was revealed that, similar to the polyhedrin protein described above in Experimental Example 1, crystals of Cry3A were obtained.
[0180] [Experimental Example 10] (Crystallization of μNS protein) In the same manner as in Experimental Example 1, the μNS protein represented by SEQ ID NO:22 was expressed using a wheat germ cell-free protein synthesis system, and the resulting protein solution was kept at 4° C. or 20° C. to form crystals. The resulting crystals were observed using an optical microscope or an electron microscope.
[0181] Figure 15A is an optical microscope image of the crystals grown at 20° C., and Figure 15B is an optical microscope image of the crystals grown at 4° C. Figure 15C is an SEM image of the crystals grown at 20° C., and Figure 15D is an SEM image of the crystals grown at 4° C. It was revealed that crystals of the μNS protein were obtained, similar to the polyhedrin protein described above in Experimental Example 1.
[0182] [Experimental Example 11] (Crystallization of Cathepsin B Protein) In the same manner as in Experimental Example 1, the cathepsin B protein represented by SEQ ID NO: 19 was expressed using a wheat germ cell-free protein synthesis system, and the resulting protein solution was kept at 4° C. or 20° C. to form crystals. The resulting crystals were observed using an optical microscope or an electron microscope.
[0183] Fig. 16A is an optical microscope image of the crystals grown at 20° C., and Fig. 16B is an optical microscope image of the crystals grown at 4° C. Fig. 16C is an SEM image of the crystals grown at 20° C., and Fig. 16D is an SEM image of the crystals grown at 4° C. It was revealed that, like the polyhedrin protein described above in Experimental Example 1, crystals of cathepsin B protein were obtained.
[0184] [Experimental Example 12] (Crystallization of nuclear polyhedral proteins) In the same manner as in Experimental Example 1, the nuclear polyhedrin protein represented by SEQ ID NO: 2 was expressed using a wheat germ cell-free protein synthesis system, and the resulting protein solution was kept at 4° C. or 20° C. to form crystals. The resulting crystals were observed using an optical microscope or an electron microscope.
[0185] Fig. 17A is an optical microscope image of the crystals grown at 20° C., and Fig. 17B is an optical microscope image of the crystals grown at 4° C. Fig. 17C is an SEM image of the crystals grown at 20° C., and Fig. 17D is an SEM image of the crystals grown at 4° C. It was revealed that, similar to the polyhedrin protein described above in Experimental Example 1, crystals of the nuclear polyhedrin protein were obtained.
[0186] [Experimental Example 13] (Crystallization of CipA) In the same manner as in Experimental Example 1, CipA represented by SEQ ID NO:24 was expressed using a wheat germ cell-free protein synthesis system, and the resulting protein solution was kept at 20° C. to form crystals. The resulting crystals were observed under an optical microscope.
[0187] 18 is an optical microscope image of the crystals produced at 20° C. It was revealed that, like the polyhedrin protein described above in Experimental Example 1, CipA crystals were obtained. [Industrial Applicability]
[0188] According to the present invention, a technique for obtaining protein crystals in a short time with little effort can be provided.
Claims
1. (a) adding a nucleic acid encoding a crystalline protein to a protein synthesis system; (b) incubating the protein synthesis system for a predetermined time until the crystalline protein encoded by the added nucleic acid is expressed and the expressed crystalline protein completes the formation of crystals; and (c) isolating the crystals, The protein synthesis system is a cell-free protein synthesis system, the predetermined time in step (b) is 64 hours or less; The temperature of the protein synthesis system in step (b) is 10° C. or higher; The method for producing a protein crystal, wherein the crystalline protein is one selected from the group consisting of the following (i) to (viii): (i) A protein consisting of the amino acid sequence set forth in SEQ ID NO: 1, or a protein consisting of the amino acid sequence set forth in SEQ ID NO: 1 in which 1 to 20 amino acids have been deleted, substituted or added, and having crystal-forming ability. (ii) A protein consisting of the amino acid sequence set forth in SEQ ID NO: 2, or a protein consisting of the amino acid sequence set forth in SEQ ID NO: 2 in which 1 to 20 amino acids have been deleted, substituted or added, and having crystal-forming ability. (iii) A protein consisting of the amino acid sequence set forth in SEQ ID NO: 18, or a protein consisting of the amino acid sequence set forth in SEQ ID NO: 18 in which 1 to 50 amino acids have been deleted, substituted or added, and having crystal-forming ability. (iv) A protein consisting of the amino acid sequence set forth in SEQ ID NO: 19, or a protein consisting of the amino acid sequence set forth in SEQ ID NO: 19 in which 1 to 20 amino acids have been deleted, substituted or added, and having crystal-forming ability. (v) a protein consisting of the amino acid sequence set forth in SEQ ID NO: 22, or a protein consisting of the amino acid sequence set forth in SEQ ID NO: 22 in which 1 to 50 amino acids have been deleted, substituted or added, and having crystal-forming ability. (vi) A protein consisting of the amino acid sequence set forth in SEQ ID NO: 24, or a protein consisting of the amino acid sequence set forth in SEQ ID NO: 24 in which 1 to 10 amino acids have been deleted, substituted or added, and having crystal-forming ability. (vii) A fusion protein of a protein selected from (i) to (vi) above with a target peptide, the protein having crystal-forming ability. (viii) a fusion protein in which the 70th to 77th amino acids in the amino acid sequence set forth in SEQ ID NO: 1 are replaced with a target peptide and which has crystal forming ability; or A protein having an amino acid sequence in which 1 to 20 amino acids are deleted, substituted or added in the fusion protein and having crystal forming ability.
2. The crystalline protein is (i) or (viii), In the step (a), 2. The method for producing a protein crystal according to claim 1, further comprising adding to the protein synthesis system a nucleic acid encoding a fusion protein having a crystal-forming ability, the fusion protein having a target peptide bound to the C-terminus of a protein consisting of the amino acid sequence set forth in SEQ ID NO: 4, or the amino acid sequence set forth in SEQ ID NO: 4 in which one amino acid has been deleted, substituted or added.
3. 3. The method for producing a protein crystal according to claim 1, wherein the cell-free protein synthesis system contains a target molecule having a molecular weight of 10 to 100,000.
4. A fusion protein in which the 70th to 77th amino acids in the amino acid sequence of SEQ ID NO: 1 are replaced with a target peptide and has crystal forming ability, or A fusion protein comprising an amino acid sequence in which 1 to 20 amino acids have been deleted, substituted or added in the above fusion protein, and having crystal forming ability.
5. A polyhedron crystallized from the fusion protein of claim 4.
6. A polyhedron-target molecule complex, in which a target molecule is encapsulated in the crystal structure of the crystallized polyhedron according to claim 5.
7. A nucleic acid encoding the fusion protein of claim 4.
8. A kit for cell-free crystal production comprising a nucleic acid encoding a crystalline protein and a reagent for cell-free protein synthesis, The cell-free crystal production kit is used for producing the protein crystal by a protein crystal production method, The production method includes the following steps (a), (b) and (c): Step (a): Adding a nucleic acid encoding a crystalline protein to a protein synthesis system Step (b): A step of incubating the protein synthesis system for a predetermined time until the crystalline protein encoded by the added nucleic acid is expressed and the expressed crystalline protein completes the formation of crystals. Step (c): Separating the crystals The predetermined time in step (b) is 64 hours or less; The temperature of the protein synthesis system in step (b) is 10° C. or higher; A kit for producing cell-free crystals, wherein the crystalline protein is one selected from the group consisting of the following (i) to (viii): (i) A protein consisting of the amino acid sequence set forth in SEQ ID NO: 1, or a protein consisting of the amino acid sequence set forth in SEQ ID NO: 1 in which 1 to 20 amino acids have been deleted, substituted or added, and having crystal-forming ability. (ii) A protein consisting of the amino acid sequence set forth in SEQ ID NO: 2, or a protein consisting of the amino acid sequence set forth in SEQ ID NO: 2 in which 1 to 20 amino acids have been deleted, substituted or added, and having crystal-forming ability. (iii) A protein consisting of the amino acid sequence set forth in SEQ ID NO: 18, or a protein consisting of the amino acid sequence set forth in SEQ ID NO: 18 in which 1 to 50 amino acids have been deleted, substituted or added, and having crystal-forming ability. (iv) A protein consisting of the amino acid sequence set forth in SEQ ID NO: 19, or a protein consisting of the amino acid sequence set forth in SEQ ID NO: 19 in which 1 to 20 amino acids have been deleted, substituted or added, and having crystal-forming ability. (v) a protein consisting of the amino acid sequence set forth in SEQ ID NO: 22, or a protein consisting of the amino acid sequence set forth in SEQ ID NO: 22 in which 1 to 50 amino acids have been deleted, substituted or added, and having crystal-forming ability. (vi) A protein consisting of the amino acid sequence set forth in SEQ ID NO: 24, or a protein consisting of the amino acid sequence set forth in SEQ ID NO: 24 in which 1 to 10 amino acids have been deleted, substituted or added, and having crystal-forming ability. (vii) A fusion protein of a protein selected from (i) to (vi) above with a target peptide, the protein having crystal-forming ability. (viii) a fusion protein in which the 70th to 77th amino acids in the amino acid sequence set forth in SEQ ID NO: 1 are replaced with a target peptide and which has crystal forming ability; or A protein having an amino acid sequence in which 1 to 20 amino acids are deleted, substituted or added in the fusion protein and having crystal forming ability.
9. The crystalline protein is (i) or (viii), The cell-free crystal production kit according to claim 8, further comprising a nucleic acid encoding a fusion protein having crystal-forming ability, the fusion protein having a target peptide bound to the C-terminus of a protein consisting of the amino acid sequence set forth in SEQ ID NO: 4, or an amino acid sequence in which one amino acid has been deleted, substituted or added in the amino acid sequence set forth in SEQ ID NO:
4.
10. A method for analyzing the three-dimensional structure of a protein crystal, comprising the steps of: Obtaining a protein crystal by the production method according to any one of claims 1 to 3; analyzing the three-dimensional structure of the protein crystal.
11. The method according to claim 10, wherein the step of analyzing the three-dimensional structure of the protein crystal is carried out by X-ray crystallography.
Citation Information
Patent Citations
Formation of polyhedra with cell-free protein synthetic system and technique for embedding protein in the same polyhedra
JP2003319778A
Modified polyhedrin protein and use thereof
JP2018033404A
